-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HFB-301001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HFB-301001 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HFB-301001 in Solid Tumor Drug Details: HFB-301001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Pruritus Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to primary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Oropharyngeal Cancer Drug Details: CMP-001 (CYT-003) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Bicarbonate in Gouty Arthritis (Gout)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Sodium Bicarbonate in Gouty Arthritis (Gout) Drug Details:Sodium bicarbonate is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sucunamostat in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sucunamostat in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sucunamostat in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Sucunamostat (SCO-792) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBFT-02 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBFT-02 in Frontotemporal Dementia (FTD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PBFT-02 in Frontotemporal Dementia (FTD)Drug Details:PBFT-02 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golcadomide in Mantle Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Golcadomide in Mantle Cell LymphomaDrug Details:CC-99282 is under development for the treatment of relapsed or refractory,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EP-547
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EP-547 Drug Details EP-547 is under developmant for the treatment of cholestatic and uremic...
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development...